阿卡波糖联合维格列汀对2型糖尿病患者血糖控制及不良反应的影响

Effect of Acarbose Combined with Vildagliptin on Blood Glucose Control and Adverse Reactions in Patients with Type 2 Diabetes Mellitus

目的阿卡波糖联合维格列汀对2型糖尿病患者血糖控制及不良反应的影响。方法按随机数字表法,将该院2018年5月-2019年4月所收治的90例2型糖尿病患者分成联合组与对照组。对照组采取阿卡波糖治疗,在此基础之上,对联合组患者再予以维格列汀治疗。对两组患者的血糖控制及不良反应发生情况进行观察与对比。结果两组患者治疗前的FBG、2 hPG、HbAlc指标相对比,差异无统计学意义(P>0.05);联合组患者治疗后FBG、2 hPG、HbAlc指标比该组治疗前以及对照组治疗后低,差异有统计学意义(P<0.05);联合组患者不良反应发生率(8.9%)低于对照组(24.4%),差异有统计学意义(χ~2=3.920,P<0.05)。结论对2型糖尿病患者采取阿卡波糖与维格列汀联合用药治疗,不但能有效控制血糖,且能减少不良反应的发生,应当在临床上进行大力的推广和使用。

Objective The effect of acarbose combined with vildagliptin on blood glucose control and adverse reactions in patients with type 2 diabetes mellitus. Methods According to the random number table method, 90 patients with type 2 diabetes admitted from May 2018 to April 2019 in the hospital were divided into the combined group and the control group.The control group was treated with acarbose, and on this basis, the patients in the combined group were treated with vildagliptin. The blood glucose control and adverse reactions occurred in the two groups were observed and compared. Results The relative values of FBG, 2 hPG and HbAlc in the two groups were not statistically significant(P>0.05). The FBG, 2 hPG and HbAlc indexes in the combined group were lower than those in the group before and after treatment. The difference was statistically significant(P<0.05). The incidence of adverse reactions in the combined group(8.9%) was lower than that in the control group(24.4%), and the difference was statistically significant(χ~2=3.920, P<0.05). Conclusion The combination of acarbose and vildagliptin in patients with type 2 diabetes can not only effectively control blood glucose, but also reduce the occurrence of adverse reactions. It should be vigorously promoted and used in clinical practice.